EA200970303A1 - Тиазолпиразолопиримидин в качестве антагониста рецептора крф1 - Google Patents

Тиазолпиразолопиримидин в качестве антагониста рецептора крф1

Info

Publication number
EA200970303A1
EA200970303A1 EA200970303A EA200970303A EA200970303A1 EA 200970303 A1 EA200970303 A1 EA 200970303A1 EA 200970303 A EA200970303 A EA 200970303A EA 200970303 A EA200970303 A EA 200970303A EA 200970303 A1 EA200970303 A1 EA 200970303A1
Authority
EA
Eurasian Patent Office
Prior art keywords
crf1
tiazoleprazoloprimidine
quality
compounds
antagonistic receptor
Prior art date
Application number
EA200970303A
Other languages
English (en)
Other versions
EA015179B1 (ru
Inventor
Чжаогэнь Чэнь
Чафик Амдоучи Амдоучи
Эрик Джеймс Хембр
Филип Артур Хипскинд
Джейсон Кеннет Майерс
Такако Такакува
Джеймс Ли Тот
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970303(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970303A1 publication Critical patent/EA200970303A1/ru
Publication of EA015179B1 publication Critical patent/EA015179B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы Iфармацевтическим композициям на основе указанных соединений и применению указанных соединений в качестве антагонистов рецепторов 1 типа кортикотропин-рилизинг-фактора (КРФ1) для лечения психических и нейроэндокринных нарушений, заболеваний нервной системы и метаболического синдрома.
EA200970303A 2006-09-20 2007-09-17 Тиазолпиразолопиримидин в качестве антагониста рецептора крф1 EA015179B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82626406P 2006-09-20 2006-09-20
PCT/US2007/078605 WO2008036579A1 (en) 2006-09-20 2007-09-17 Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Publications (2)

Publication Number Publication Date
EA200970303A1 true EA200970303A1 (ru) 2009-10-30
EA015179B1 EA015179B1 (ru) 2011-06-30

Family

ID=38924802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970303A EA015179B1 (ru) 2006-09-20 2007-09-17 Тиазолпиразолопиримидин в качестве антагониста рецептора крф1

Country Status (34)

Country Link
US (1) US8030304B2 (ru)
EP (1) EP2094709B1 (ru)
JP (1) JP5161226B2 (ru)
KR (1) KR101088239B1 (ru)
CN (1) CN101516887B (ru)
AR (1) AR062886A1 (ru)
AT (1) ATE481405T1 (ru)
AU (1) AU2007297421B2 (ru)
BR (1) BRPI0717023B8 (ru)
CA (1) CA2663511C (ru)
CL (1) CL2007002693A1 (ru)
CR (1) CR10682A (ru)
CY (1) CY1110854T1 (ru)
DE (1) DE602007009305D1 (ru)
DK (1) DK2094709T3 (ru)
EA (1) EA015179B1 (ru)
ES (1) ES2350282T3 (ru)
HK (1) HK1132505A1 (ru)
HR (1) HRP20100516T1 (ru)
IL (1) IL197614A (ru)
MA (1) MA30798B1 (ru)
MX (1) MX2009003125A (ru)
MY (1) MY146388A (ru)
NO (1) NO20091489L (ru)
NZ (1) NZ575572A (ru)
PE (1) PE20081377A1 (ru)
PL (1) PL2094709T3 (ru)
PT (1) PT2094709E (ru)
RS (1) RS51545B (ru)
SI (1) SI2094709T1 (ru)
TN (1) TN2009000095A1 (ru)
TW (1) TWI402269B (ru)
UA (1) UA96458C2 (ru)
WO (1) WO2008036579A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
BRPI0920838A2 (pt) * 2008-10-02 2018-10-16 Lilly Co Eli composto de tiazolil-pirazolopirimidina como intermediários sintéticos e processos sintéticos relacionados
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2936974A1 (en) * 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
EP3510029A4 (en) 2016-09-07 2020-03-11 The Regents of The University of California ALLOSTERIC CORTICOTROPIN RELEASING FACTOR-1 (CRFR1) ANTAGONISTS TO REDUCE P-TAU AND IMPROVE THE COGNITION
US20210361664A1 (en) 2017-08-14 2021-11-25 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
MX2019015318A (es) * 2017-08-14 2020-07-20 Spruce Biosciences Inc Antagonistas del receptor del factor liberador de corticotropina.
EP3784233B1 (en) * 2018-04-27 2024-06-05 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN109134481B (zh) * 2018-08-07 2021-05-14 中山大学 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) * 2018-09-04 2020-12-21 美商美國禮來大藥廠 2,6-二胺基吡啶化合物
WO2021113263A1 (en) * 2019-12-04 2021-06-10 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
KR20230043222A (ko) * 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
WO2022046905A1 (en) 2020-08-26 2022-03-03 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
CA3235958A1 (en) * 2021-11-19 2023-05-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (en) * 2022-02-23 2023-08-31 Crinetics Pharmaceuticals, Inc. Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6765008B1 (en) 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
CZ244598A3 (cs) * 1996-02-07 1998-10-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidiny jako antagonisty CRF receptoru
EA004403B1 (ru) * 1996-07-24 2004-04-29 Дюпон Фармасьютикалз Компани Производные пиразолотриазинов, фармацевтические композиции, содержащие их, способы лечения
EP1908764A1 (en) 1996-07-24 2008-04-09 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
EP1040831A3 (en) * 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
WO2000059908A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
CZ20021089A3 (cs) 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
CZ20032481A3 (cs) * 2001-03-13 2007-12-27 Bristol-Myers Squibb Pharma Company 4-(2-Butylamino)-2, 7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)pyrazolo[1,5-A]-1, 3, 5-triazin, jeho enantiomery a farmaceuticky prijatelné soli jakoligandy receptoru faktoru uvolnujícího kortikotropin
NZ547990A (en) 2003-12-22 2010-04-30 Smithkline Beecham Cork Ltd CRF receptor antagonists and methods relating thereto

Also Published As

Publication number Publication date
NZ575572A (en) 2011-10-28
KR20090052366A (ko) 2009-05-25
IL197614A (en) 2012-10-31
CL2007002693A1 (es) 2008-04-18
EP2094709B1 (en) 2010-09-15
CY1110854T1 (el) 2015-06-10
KR101088239B1 (ko) 2011-11-30
CR10682A (es) 2009-08-13
BRPI0717023B1 (pt) 2019-11-19
JP5161226B2 (ja) 2013-03-13
PE20081377A1 (es) 2008-09-18
ES2350282T3 (es) 2011-01-20
TN2009000095A1 (en) 2010-08-19
ATE481405T1 (de) 2010-10-15
PT2094709E (pt) 2010-10-04
JP2010504344A (ja) 2010-02-12
DK2094709T3 (da) 2010-12-06
MX2009003125A (es) 2009-05-28
BRPI0717023B8 (pt) 2021-05-25
EA015179B1 (ru) 2011-06-30
AU2007297421A1 (en) 2008-03-27
HRP20100516T1 (hr) 2010-10-31
MY146388A (en) 2012-08-15
US8030304B2 (en) 2011-10-04
MA30798B1 (fr) 2009-10-01
BRPI0717023A2 (pt) 2014-03-11
HK1132505A1 (en) 2010-02-26
TW200821312A (en) 2008-05-16
PL2094709T3 (pl) 2011-02-28
AU2007297421B2 (en) 2012-03-08
TWI402269B (zh) 2013-07-21
IL197614A0 (en) 2009-12-24
RS51545B (en) 2011-06-30
US20100222339A1 (en) 2010-09-02
NO20091489L (no) 2009-04-16
WO2008036579A1 (en) 2008-03-27
CA2663511C (en) 2012-12-04
DE602007009305D1 (de) 2010-10-28
EP2094709A1 (en) 2009-09-02
CA2663511A1 (en) 2008-03-27
AR062886A1 (es) 2008-12-10
CN101516887B (zh) 2011-11-02
SI2094709T1 (sl) 2011-01-31
CN101516887A (zh) 2009-08-26
UA96458C2 (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
EA200970303A1 (ru) Тиазолпиразолопиримидин в качестве антагониста рецептора крф1
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
CY1109069T1 (el) Ενωσεις ιμιδαζοπυριδαζινης
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200701705A1 (ru) Антагонисты рецепторы глюкагона, получение и терапевтическое применение
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA200970085A1 (ru) Замещённые n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения
MY161834A (en) Substituted diazepan compounds as orexin receptor antagonists
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
EA200700027A1 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
DE602005023124D1 (de) Spirobenzodioxole und deren verwendung als cb1-antagonisten
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
EA201190208A1 (ru) Соединения для лечения метаболических расстройств
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
EA200802104A1 (ru) Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ TJ RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): AZ TJ RU